Compare Ginkgo Bioworks Holdings Inc (DNA) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs BlackRock TCP Capital Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while BlackRock TCP Capital Corp trades at $4.01 (market cap $337.71M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 2.3× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and BlackRock TCP Capital Corp for 88 Days on average.
| DNA | TCPC | |
|---|---|---|
Market Cap | $763.64M | $337.71M |
Volume | 3,204,177 | 436,109 |
Sector | Health | Financials |
52-Week High | $15.83 | $6.20 |
52-Week Low | $5.48 | $3.13 |
Typical Hold Time | 7 Days | 88 Days |
Enterprise Value | $865.59M | $1.09B |
Dividend Yield | — | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
TCPC trades at $4.03, up 2.28% today, with a bullish technical signal from moving averages. The company reported negative revenue and net income for 2025 but beat Q2 2026 earnings expectations. Recent portfolio sales have reduced leverage and prompted a strategic review. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
The outlook remains cautious due to negative profitability metrics and declining revenue trends, though recent strategic moves and technical strength offer potential upside. Key risks include ongoing negative cash flow, class action lawsuits, and execution challenges in the private credit market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
